2004
DOI: 10.1097/01.mjt.0000133582.68709.e3
|View full text |Cite
|
Sign up to set email alerts
|

Chemotherapy for Prostate Cancer

Abstract: Patients with metastatic prostate cancer can be treated with androgen deprivation strategies; however, most patients will eventually develop androgen-independent prostate cancer (AIPC). Until recently, chemotherapy has been shown to palliate symptoms of disease but not improve survival. Now 2 large phase 3 trials have demonstrated an overall survival advantage for docetaxel-based regimens compared with the best standard of care. This firmly cements docetaxel-based therapies as the standard of care for patients… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
17
0
1

Year Published

2006
2006
2015
2015

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 19 publications
(18 citation statements)
references
References 33 publications
(34 reference statements)
0
17
0
1
Order By: Relevance
“…[270][271][272][273][274][275] Employing the use of these drugs, however, has been met with only modest success due to issues of toxicity and the drug-resistant nature of CaP. Efforts to minimize drug resistance should prove effective in extending the life expectancy of HRPC patients.…”
Section: Treatment Of Prostate Cancermentioning
confidence: 99%
“…[270][271][272][273][274][275] Employing the use of these drugs, however, has been met with only modest success due to issues of toxicity and the drug-resistant nature of CaP. Efforts to minimize drug resistance should prove effective in extending the life expectancy of HRPC patients.…”
Section: Treatment Of Prostate Cancermentioning
confidence: 99%
“…Hormone-refractory or androgenindependent prostate cancer has proven to be largely resistant to conventional chemotherapy. With the exception of palliative care, the only approved chemotherapy is docetaxel in combination with prednisone, which offers a modest (2.4 months) survival benefit (4,5). New molecularly targeted therapies are urgently needed.…”
mentioning
confidence: 99%
“…The currently Food and Drug Administration (FDA) approved first-line chemotherapeutic agents for CRPC treatment include mitoxantrone (an anthracycline derivative [7,8], estramustine (an estrogen derivative), and docetaxel [9] Fig. (b).…”
Section: Introductionmentioning
confidence: 99%
“…Since 2004 combined administration of docetaxel (tradename Taxotere) and prednisone has been the standard first-line treatment for metastatic CRPC [9,13,14]. Additionally, docetaxel/ estramustine combinations were proposed as first-line chemotherapy against advanced prostate cancer and verified to be active, with tolerable side effects [14][15][16][17].…”
Section: Introductionmentioning
confidence: 99%